Eisai Co., Ltd. (ESALF) は上場企業です ヘルスケア セクターの Drug Manufacturers - Specialty & Generic 業界で事業展開. 本社所在地は Tokyo, 日本. 現CEOは Haruo Naito.
ESALF を有する IPO日 2011-04-07, 11,067 名の正社員, に上場 Other OTC, 時価総額 $8.46B.
Eisai Co., Ltd. is a Tokyo-based pharmaceutical company founded in 1941 that develops and markets a diverse portfolio of prescription and over-the-counter products across multiple therapeutic areas. The company's key branded medications include Aricept for Alzheimer's disease and Lewy body dementia, Fycompa for epilepsy, Dayvigo for insomnia, and Lenvima for various cancers including thyroid, renal cell, and hepatocellular carcinoma. Eisai also markets Halaven for breast cancer and liposarcoma, Lyrica for pain management, Pariet for gastrointestinal disorders, and Humira for autoimmune diseases, alongside consumer health products such as vitamin supplements and designated quasi-drugs. The company serves the Japanese market as a leading player in both prescription pharmaceuticals and consumer health categories.
